Home › Compare › MRLWF vs ABBV
MRLWF yields 33.17% · ABBV yields 3.06%● Live data
📍 MRLWF pulled ahead of the other in Year 1
Combined, MRLWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MRLWF + ABBV for your $10,000?
Marlowe plc provides compliance services and software in the United Kingdom. The company operates in two segments, Governance, Risk & Compliance; and Testing, Inspection & Certification. It offers health and safety, HR and employment law compliance, occupational health, and risk management software; a range of fire safety and security services; and integrated water treatment, hygiene, testing, monitoring, wastewater, and engineering services. The company is also involved in the provision of testing, inspection and risk assessment, ventilation hygiene compliance, ductwork management and fire safety, extract cleaning, asbestos consultancy, air monitoring and clearance testing, and bulk identification and sampling services. Its customers include office complexes, streets, leisure facilities, manufacturing plants and industrial estates, SMEs, local corporates and authorities, other facilities, property management providers, NHS trusts, and FTSE companies. Marlowe plc was formerly known as Marlowe Holdings Limited. The company was founded in 2015 and is headquartered in London, the United Kingdom.
Full MRLWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.